iPSC-Derived Organoids as Therapeutic Models in Regenerative Medicine and Oncology

Frontiers in Medicine

Jinwook W. Hwang¹  Ali G. Turhan²  Annelise Bennaceur-Griscelli²  Theodoros Latsis³  Christophe Desterke³  Diana Chaker⁴  Albert Tasteyre⁴  Frank Griscelli⁵ 

[1] INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France;ESTeam Paris Sud, Université Paris Saclay, Villejuif, France;INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France;ESTeam Paris Sud, Université Paris Saclay, Villejuif, France;APHP Paris Saclay, Department of Hematology, Hopital Bicetre and Paul Brousse, Villejuif, France;INGESTEM National iPSC Infrastructure, Villejuif, France;CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Genopole, Evry, France;INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France;ESTeam Paris Sud, Université Paris Saclay, Villejuif, France;INGESTEM National iPSC Infrastructure, Villejuif, France;INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France;ESTeam Paris Sud, Université Paris Saclay, Villejuif, France;INGESTEM National iPSC Infrastructure, Villejuif, France;CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Genopole, Evry, France;INSERM UA/09 UMR-S 935, Université Paris Saclay, Villejuif, France;ESTeam Paris Sud, Université Paris Saclay, Villejuif, France;INGESTEM National iPSC Infrastructure, Villejuif, France;CITHERA, Centre for IPSC Therapies, INSERM UMS-45, Genopole, Evry, France;Université Paris Descartes, Faculté Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France;

关键词: induced pluripotent stem (IPS) cell;    organoid;    cancer;    drug discovery;    regenerative medicine;   

DOI  :  10.3389/fmed.2021.728543

来源: Frontiers

【 摘 要 】

Progress made during the last decade in stem cell biology allows currently an unprecedented potential to translate these advances into the clinical applications and to shape the future of regenerative medicine. Organoid technology is amongst these major developments, derived from primary tissues or more recently, from induced pluripotent stem cells (iPSC). The use of iPSC technology offers the possibility of cancer modeling especially in hereditary cancers with germline oncogenic mutations. Similarly, it has the advantage to be amenable to genome editing with introduction of specific oncogenic alterations using CRISPR-mediated gene editing. In the field of regenerative medicine, iPSC-derived organoids hold promise for the generation of future advanced therapeutic medicinal products (ATMP) for organ repair. Finally, it appears that they can be of highly useful experimental tools to determine cell targets of SARS-Cov-2 infections allowing to test anti-Covid drugs. Thus, with the possibilities of genomic editing and the development of new protocols for differentiation toward functional tissues, it is expected that iPSC-derived organoid technology will represent also a therapeutic tool in all areas of medicine.

【 授权许可】

CC BY